One email when the decision is public, with what it means in plain language. You'll also get new trials and FDA news for Stargardt Disease. Unsubscribe anytime.
- Trial Alerts, when a new trial opens or a trial changes
- Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
The FDA is expected to decide on Tinlarebant for Stargardt disease type 1 by February 12, 2027, under an NDA from Belite Bio.
What the FDA is deciding on Tinlarebant for Stargardt disease type 1
The FDA is reviewing Belite Bio's application to approve Tinlarebant for stargardt disease type 1. Would be the first approved treatment for Stargardt disease.
Who the Tinlarebant decision matters to
Stargardt disease is the most common inherited macular dystrophy, caused primarily by mutations in the ABCA4 gene that lead to toxic accumulation of lipofuscin (a waste byproduct of the visual cycle) in retinal pigment epithelial cells. This accumulation progressively destroys the macula, the central part of the retina responsible for sharp, detailed vision, resulting in progressive central vision loss that typically begins in childhood or adolescence.
Prevalence: Approximately 1 in 8,000 to 10,000 people; an estimated 30,000 affected individuals in the U.S. See our full Stargardt Disease page for current treatments, recruiting trials, and community resources.
What an approval or a rejection of Tinlarebant would mean
An approval starts a second race rather than ending the first one: specialty pharmacy setup, insurance review, and patient assistance typically take weeks even when everything goes right. Our guide to the 90 days after a rare disease approval explains the timeline and the moves families can make on day 1.
A complete response letter would mean the FDA declined to approve in the application's current form. The letter describes what the FDA wants addressed, and the company then decides whether to resubmit, run more studies or stop. Either way, this page updates with the outcome and what it means.
Where Stargardt Disease treatment stands today
Read our full Stargardt Disease treatment summary
Stargardt disease has no FDA-approved therapy, but the clinical trial pipeline is one of the most active in inherited retinal disease. Gene therapy approaches using dual-vector AAV systems (the ABCA4 gene is too large for a single AAV vector) are in Phase 1/2 trials.
Tinlarebant, an oral pill that slows the visual cycle to cut the buildup of lipofuscin, slowed the growth of retinal lesions by 35.7% compared with placebo in the Phase 3 DRAGON trial, and the FDA is due to decide on it by February 12, 2027. Optogenetic therapies and RNA editing approaches are also in early trials.
Ask your retinal specialist about your specific ABCA4 mutations (genotype-phenotype correlations can inform prognosis), whether your current disease stage makes you eligible for active gene therapy or pharmacological trials, and whether low-vision rehabilitation services should begin now. Register with the MyRetinaTracker registry through the Foundation Fighting Blindness to be matched with trials as they open.
The Stargardt Disease page has every treatment and trial →Meanwhile, 24 Stargardt Disease studies are open or about to open
Whatever the FDA decides here, research on Stargardt Disease does not stop. Of these, 14 test a treatment; the others follow patients over time. The most recently updated:
We'll email you when the decision is public, with what it means in plain language, and when new trials open for Stargardt Disease. Unsubscribe anytime.
- Trial Alerts, when a new trial opens or a trial changes
- Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Frequently asked questions
When will the FDA decide on Tinlarebant?
The FDA's target date (PDUFA date) for Tinlarebant in Stargardt disease type 1 is February 12, 2027.
Who disclosed it: Belite Bio. The FDA does not publish these dates.
Can it move: the FDA can act early, and a major amendment to the application can push the date back 3 months.
Source: Belite Bio press release
What is Tinlarebant being reviewed for?
Belite Bio submitted an NDA for Tinlarebant in Stargardt disease type 1.
What to know: Would be the first approved treatment for Stargardt disease.
Is there already an FDA-approved treatment for Stargardt Disease?
No. No medicine's current FDA label names Stargardt Disease, checked October 21, 2026.
Check: the Stargardt Disease page also searches FDA drug labels for approved treatments.
Can I get Tinlarebant before the FDA decides?
Usually only through a clinical trial or an expanded access program, and the company decides whether to offer one.
Trials: 24 Stargardt Disease studies are open or about to open, 14 of them testing a treatment. See them.
Check your fit: Match Me compares your details with every open trial.
Expanded access: your doctor can ask Belite Bio directly. Registered programs are listed on ClinicalTrials.gov.
How much will Tinlarebant cost?
Belite Bio has not announced a price. Drugmakers usually set it around approval.
Help paying: drugmaker programs and charity funds usually open at launch.
Find help: the patient assistance finder lists programs by insurance type.
What happens after the Tinlarebant decision?
This page updates with the outcome the day it is announced.
If approved: getting the drug still takes time. Specialty pharmacy setup, insurance review and patient assistance often take weeks. Our guide covers what families can do on day 1.
If not approved: a complete response letter means the FDA declined the application in its current form. Many are about manufacturing or how data were presented, and companies often resubmit.
Where this date comes from
The FDA does not publish PDUFA dates; companies disclose them. This one comes from Belite Bio press release. Dates can move, and the FDA can act early or late. This page rechecks against our calendar, which is re-verified daily.